Related Experiment Videos
[Experimental gene therapy in models of inflammatory arthritis]
N Bessis1, C Fournier, D Fradelizi
1Unité de Recherches sur l'Immunorégulation et l'Auto-immunité (INSERM U283), Université René-Descartes, Paris.
Abstract:
Gene therapy is rheumatoid arthritis is presently in an experimental phase. Genes encoding for antiinflammatory proteins can be transfected in joint cells. Therefore gene encoding for interleukin-1 receptor antagonist has been transfected into synovial cells or into chondrocytes. Gene expression can be maintained as long as 8 weeks after cell transfer. We have reported that clinical and histopathological parameters of collagen-induced arthritis (an animal model of rheumatoid arthritis) can be reduced by engraftment of CHO cells transfected with genes encoding for antiinflammatory cytokines such as interleukine-4 or interleukine-13. Some of the questions which need to be assessed before planning clinical trial are the choice of vectors and the most efficient target cells; and the genes to be transfected have to be chosen among many candidates.
Insights
Gene therapy shows promise for rheumatoid arthritis by using anti-inflammatory genes in joint cells. This experimental approach aims to reduce disease symptoms and inflammation effectively.
Area of Science:
- * Molecular biology and immunology
- * Gene therapy applications in autoimmune diseases
Context:
- * Rheumatoid arthritis (RA) is a chronic autoimmune disease causing joint inflammation.
- * Current RA treatments focus on symptom management, with limitations.
- * Gene therapy offers a novel therapeutic strategy for RA.
Purpose:
- * To investigate the potential of gene therapy for treating rheumatoid arthritis.
- * To evaluate the efficacy of transfecting genes encoding anti-inflammatory proteins into joint cells.
- * To assess the feasibility of using cytokine-encoding genes to reduce RA pathology.
Summary:
- * Experimental gene therapy involves transfecting genes for anti-inflammatory proteins, such as interleukin-1 receptor antagonist, into synovial cells or chondrocytes.
- * Successful gene expression was maintained for up to 8 weeks post-cell transfer.
- * Engraftment of cells transfected with interleukin-4 or interleukin-13 genes reduced clinical and histopathological signs in a collagen-induced arthritis model.
Impact:
- * Provides a foundation for developing novel gene-based therapies for rheumatoid arthritis.
- * Highlights key considerations for future clinical trials, including vector selection and target cell identification.
- * Suggests potential for long-term disease modification in RA patients.